Cybin Inc. (HELP) AI Stock Analysis

Helus Pharma Inc. operates as a clinical stage pharmaceutical company focused on developing therapies for psychiatric and neurological conditions. Its pipeline includes HLP003, a deuterated psilocybin analog in phase 3 clinical trials for major depressive disorder, and HLP004, a deuterated N, N-dimethyltryptamine in phase 2 trials for generalized anxiety disorders. Preclinical assets include HLP005 for central nervous system conditions. The company maintains strategic partnerships with Segal Trials and Osmind, and operates across Canada, the United States, the United Kingdom, and Ireland.

Helus Pharma recorded $0 in trailing twelve-month revenue as of June 30, 2026, reflecting its clinical-stage status. In FY2026, revenue was reported at -$44.7M compared to $472,270 in FY2025 and -$18.1M in FY2024. Operating losses expanded over this period, driven by rising research and development expenses that reached $86.0M in FY2026, up from $54.9M in FY2025 and $32.4M in FY2024. Consequently, net losses widened from -$47.5M in FY2023 and -$78.1M in FY2024 to -$113.1M in FY2025 and -$147.1M in FY2026, resulting in an FY2026 EPS of -$5.00.

As of June 30, 2026, Helus Pharma held $166.2M in cash and short-term investments, total assets of $259.3M, and shareholders' equity of $241.8M. The company maintains a current ratio of 10.97. Operations consumed cash in FY2026, with an operating cash flow of -$132.4M and free cash flow of -$133.8M after capital expenditures of $1.4M. To finance its clinical programs, the company's share count expanded by 1057.0% over the trailing five-year period.

At a share price of $10.55 as of October 16, 2026, Helus Pharma has a market capitalization of $770.8M and an enterprise value of $909.2M. The stock trades at a price-to-book ratio of 3.9x. Because it has $0 in trailing twelve-month revenue, traditional earnings and sales multiples are not applicable, whereas the median of its US-listed Healthcare peers trades at a trailing P/E of 24.6x and a price-to-sales multiple of 4.1x. Over the past year, the stock returned 73.0% compared to 16.8% for the S&P 500, though its five-year return stands at -85.9% versus 83.0% for the S&P 500.

Wall Street coverage consists of 10 Strong Buy ratings, 1 Buy rating, and no Hold or Sell recommendations. The mean price target is $40.44, representing an implied upside of 283.3% from the last closing price of $10.55. For the current fiscal year ending March 31, 2027, consensus estimates project $0 in revenue and an EPS of -$3.72. For the following fiscal year, 2 analysts project revenue of $11.1M and an EPS of -$2.54. The company beat EPS estimates in 1 of the last 4 quarters, with its next earnings announcement scheduled for November 12, 2026.

This page is an AI-written research summary of Cybin Inc. (HELP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HELP income statement, HELP balance sheet, HELP key metrics, HELP analyst forecast, HELP chart. See the HELP stock overview for the latest quote and news.